Helmut M. Schühsler
Chairman and CEO @ TVM Capital Healthcare
Helmut M. Schühsler is a Series B investor at TVM Capital Healthcare focused on Health Care and Biotechnology. Helmut M. Schühsler - Chairman and CEO @ TVM Capital Healthcare
- Total investments:
- 4
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries Helmut M. Schühsler invests in
Stages Helmut M. Schühsler invests in
Countries Helmut M. Schühsler invests in
Investment Focus
Industry
- Health Care 4 (100%)
- Biotechnology 3 (75%)
- Medical 1 (25%)
- Genetics 1 (25%)
- Oncology 1 (25%)
Stage
- Series B 2 (50%)
- Funding Round 1 (25%)
- Private Equity 1 (25%)
Country
- United States 3 (75%)
- Saudi Arabia 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Baraya Extended Care
|
Baraya is a company specializing in rehabilitation treatment, committed to providing high-quality rehabilitation treatment services to patients. | $124M / Series B / Jul 15, 2025 | |
Human Longevity
|
Human Longevity (HLI) is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. Its business areas include the HLI Health Nucleus, a genomicpowered clinical research center that uses whole-genome sequence analysis, advanced clinical imaging, and innovative machine learning, along with curated personal health information to deliver the most complete picture of individual health; HLIQ Whole Genome and HLIQ Oncology. It was founded in 2013 and is headquartered in San Diego, California. | $39.8M / Series B / Aug 21, 2024 | |
Boston Oncology
|
At Boston Oncology, we support the healthcare of citizens in emerging markets around the world through regional development and production of licensed biopharmaceutical products. | $35M / Private Equity / Jun 26, 2024 | |
SelectX Pharmaceuticals Inc.
|
SelectX Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery and development of aminoglycoside therapeutics for unmet medical needs. It has built an advanced aminoglycoside drug and other drugs. The company’s advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistantgram-negative hospital-acquired infections.SelectX Pharmaceuticals Inc. is currently developing a next generation inhaled aminoglycoside antibiotic for drug resistant gram-negative infections in patients with Cystic Fibrosis and other respiratory diseases. The company is based in Boston, Massachusetts. | Jan 01, 2002 |
Co-Investors
About TVM Capital Healthcare
TVM Capital Healthcare is a highly focused private equity and growth capital firm.
TVM Capital Healthcare Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Farid Fezou
Managing Partner
|
|||
|
Farid Fezoua
Managing Partner
|
|||
|
Helmut M. Schühsler
Chairman and CEO
|
|||
Hoda Abou-Jamra
Founding Partner
|
|||
Orhan Osmansoy
Operating Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Helmut M. Schühsler invest in?
Helmut M. Schühsler invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Funding Round stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Helmut M. Schühsler last invest?
The most recent investment recorded for Helmut M. Schühsler closed in Jul 2025. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
